We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 01:00:00 |
From Oct 2023 to Apr 2024
By Will Feuer
Merck said the Food and Drug Administration has accepted for priority review the company's V116 investigational pneumococcal conjugate vaccine.
Merck said the FDA has set a target action date of June 17 for the review. The FDA grants priority review to drugs and vaccines that would provide a significant improvement in the safety, effectiveness of the treatment or prevention of a serious condition.
"Invasive pneumococcal disease poses a greater risk to older adults or those with weakened immune systems," said Eliav Barr, Merck Research Laboratories' chief medical officer.
Barr said V116 would be the first pneumococcal conjugate vaccine specifically designed to address the serotypes that cause most adult invasive pneumococcal disease.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
December 19, 2023 07:14 ET (12:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
